Home > > Pharmaceuticals and Healthcare > > Crizotinib Market Size & Forecast 2032 | CAGR 5.6%
Crizotinib Market Size & Industry Share - Growth Trends & Forecasts (2023 - 2031)
ID : CBI_1367 | Updated on : | Author : Yogesh K | Category : Pharmaceuticals and Healthcare
Crizotinib Market Size :
Crizotinib Market size is estimated to reach over USD 1,495.21 Million by 2032 from a value of USD 998.59 Million in 2024 and is projected to grow by USD 1,032.90 Million in 2025, growing at a CAGR of 5.6% from 2025 to 2032.
Crizotinib Market Definition & Overview:
Crizotinib is a medication prescribed for non-small cell lung cancer (NSCLC). The medicine works by slowing the progress of cancer cells, essentially impeding tumor development. Also, the drug is considered an antineoplastic agent as it interferes with the increase of cancer cells, leading to their destruction by the body. Further, the medicine is a tyrosine kinase receptor inhibitor and falls under a category of targeted therapy drugs known as cancer growth inhibitors. It's particularly effective for NSCLC when the cancer has specific gene rearrangements, namely ALK-positive and ROS1-positive. Furthermore, key trends including the development of New ALK Inhibitors, advancements in targeted therapy, cost effectiveness, rising awareness and stiff competitive landscape among others are significantly impacting the crizotinib market size.
Key Regional Insights
- North America market expected to grow to USD 520.48 million by 2032, led by United States with 64.20% share
- Growth driven by presence of key players and rising adoption of precision medicine and targeted therapies
- Asia Pacific expected to grow fastest (6.0% CAGR) due to rising awareness and better diagnostics
- U.S. Food and Drug Administration approved new formulation of Crizotinib (Xalkori)
Crizotinib Market Dynamics - (DRO) :
Key Drivers:
Increasing Prevalence of Non-Small Cell Lung Cancers is Driving the Market
The crizotinib drug is commonly used in the treatment of non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers consisting of adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, among others. The symptom of this cancer includes shortness of breath, prolonged cough, weight loss, and blood coughing. This disease is treated with chemotherapy, surgery, immunotherapy, and radiation therapy among others. Additionally, non-small cell lung cancers are controlled by blocking the growth of cancerous cells. Further, the increase in the prevalence of lung cancer across the world is driving the growth of non-small cell lung cancer in turn driving the crizotinib market share. In addition, growing non-small cell lung cancers also influence the demand for the drug in the market. Furthermore, enhanced diagnostic techniques and increased awareness contribute to earlier detection, expanding the patient pool eligible for these novel therapeutics.
- For instance, according to the American Society of Clinical Oncology, lung cancer is the second most diagnosed cancer worldwide. Moreover, non-small cell lung cancers (NSLC) account for 80% to 85% of all lung cancers.
Thus, the increasing prevalence of non-small cell lung cancer, owing to overall spikes in all kinds of lung cancers in turn driving the crizotinib market size.
Key Restraints :
Side Effects Associated with the Consumption of the Drug are Restraining the Crizotinib Market Growth
Crizotinib, while effective for certain ALK-positive cancers like NSCLC, faces significant market growth restraint due to its associated side effects. Common adverse events include nausea, vomiting, diarrhea, visual disturbances, and fatigue. Further, more severe or less frequent side effects including liver dysfunction, interstitial lung disease, and cardiac rhythm abnormalities can lead to dose reduction or even treatment discontinuation. These adverse events impact patient adherence and overall quality of life. Furthermore, the emergence of newer, more tolerable ALK inhibitors with improved side effect profiles presents a competitive challenge. Thus, the competitive landscape, driven by patient safety and tolerability concerns, limits the crizotinib market expansion.
Future Opportunities:
Expansion of Crizotinib Drug Applications in Other Types of Cancers is Expected to Drive Crizotinib Market Opportunities
The extension of drug applications into other cancer types is anticipated to drive market growth throughout the forecast period. The promising trajectory is reinforced by growing scientific understanding of drug's mechanism of action, which targets specific genetic alterations like MET, ROS1, and ALK, found not only in NSCLC but also, albeit rarely, in other malignancies. Moreover, the versatility of the drug as a potent cancer cell blocker suggests its efficacy could extend to other malignancies. This broader potential is supported by preclinical evidence, such as a study published in the Journal of Medical Oncology in January 2021. This research demonstrated that the drug's successfully inhibited the growth of both MCF7 and T-47D breast cancer cell lines in laboratory settings. Such findings provide a strong foundation for further clinical investigation into the drug's applicability across a wider spectrum of cancer types, potentially offering new treatment options for patients with challenging diagnoses.
Thus, the expanded application of the drug beyond its current uses is anticipated to drive crizotinib market opportunities.
Segmental Analysis:
By Capsule:
Based on Capsule, the market is categorized into 200mg capsule and 250mg capsule.
Trend in the Capsule:
- 200mg capsule plays a crucial role in enabling dose reductions for patients experiencing adverse events or who require a lower initial dose due to comorbidities.
- Increasing need for dose flexibility in long-term targeted therapies drives the demand for the 200mg capsule in turn driving the crizotinib market growth.
250mg capsule holds the largest revenue share in the year 2024 and is expected to grow at the fastest CAGR during the forecast period.
- 250mg capsule is the standard and most common initial dosing for adult patients with ALK-positive or ROS1-positive NSCLC, given twice daily.
- 250mg capsule benefits from a long-standing, well-established efficacy and safety profile which in turn drives the crizotinib market demand.
- Increasing trends of rising awareness and technological advancement in healthcare further dries the crizotinib market trends.
- For instance, according to Centre for Disease Control and Prevention, approximately 12 out of 100 adults in the U.S. smoked cigarettes in 2022, accounting for a total of 28.8 million adults in the United States. The prevalence of smoking results in increased cases of lung cancer which in turn drives the market.
- Thus, as per crizotinib market analysis, dominant initial dosing and well-established efficacy are significantly driving the market.
By Application:
Based on application, the market is categorized into ALK-positive NSCLC and ROS1-positive NSCLC.
Trend in the Application:
- The overall market for ROS1-positive NSCLC therapies, including Crizotinib, benefits from increased awareness and broader adoption of biomarker
ALK-positive NSCLC holds the largest revenue share of 83.79% in the year 2024 and is anticipated to have the highest CAGR during the forecast period.
- Evolving treatment landscape rising from first to third-generation ALK Inhibitors (ALKi) drives the crizotinib market trends.
- Further, the drug maintains a steady demand due to its proven efficacy and often lower costs compared to newer generations in turn driving the crizotinib market demand.
- Furthermore, increased use in later lines of therapy, advancement in treatment landscape, and rising awareness drive the market.
- For instance, according to the data published by the American lung association in November 2022 approximately 4% patients of lung cancer are ALK-positive and 1-2% are ROS1-positive. Thus, the higher prevalence of ALK-positive rearrangements in NSCLC is influencing the market.
- Thus, as per crizotinib market analysis, technological advancements in treatment landscape, lower costs and rising awareness drive the crizotinib market expansion.
Regional Analysis:
The regions covered are North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America valued at USD 345.01 Million in 2024 and USD 357.08 Million in 2025 and is expected to reach USD 520.48 Million in 2032. In the North American region, the U.S. accounted for the highest market share of 64.20% in 2024. The prevalence of the crizotinib market in North American countries is attributed to the presence major key players in the region. Additionally, an increased preference for precision medicine and targeted therapy is also driving the market.
- For instance, according to the data published by the Lung Cancer Foundation of America in July 2023, ALK-positive non-small cell lung cancer occurs in 1 out of 25 NSCLC patients, and younger patients generally of age 55 And below, who have never smoked are more likely to be diagnosed with ALK-positive NSCLC.
Moreover, as per analysis, the Asia Pacific region is expected to grow at the fastest CAGR of 6.0% during the forecast period. The rise in the region is attributed to increasing awareness, rising preference for advanced and better diagnostic procedures and increasing prevalence of lung cancers.
- For instance, in September 2023, the FDA approved an oral pellet formulation of Pfizer's Crizotinib product, Xalkori, which was previously only available as an oral capsule.
The regional trends analysis depicts that stringent regulation in healthcare industry and presence of well-established healthcare infrastructure in Europe are driving the market. Additionally, according to analysis, the factors driving the market in the Middle East and African region are improving healthcare industry, and rising awareness about targeted therapies. Further, based on analysis incidence of ALK-positive and ROS1-positive NSCLC, and efforts to improve access to advanced diagnostics are paving the way for the progress of market trends in the Latin American region.
Top Key Players & Market Share Insights:
The global crizotinib market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The crizotinib industry is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the crizotinib industry include-
- Pfizer (US)
- Bulat Pharmaceutical (India)
- DEAFARMA (Italy)
- Incepta Pharmaceuticals Ltd (Bangladesh)
- WUHAN HANWAYS PHARMCHEM CO., LTD. (China)
- Beacon Pharmaceuticals PLC (Bangladesh)
- LGM Pharma (US)
- Hefei Home Sunshine Pharmaceutical Technology Co., Ltd (China)
- Selleck Chemicals (US)
- Shanghai Hope-Chem Co., Ltd (China)
Recent Industry Developments:
- In September 2022, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) approved 2 new suggestions, recommending crizotinib product of Pfizer for the treatment of paediatric patients with anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumour (IMT).
- In September 2023, the FDA approved the new formulation of Pfizer's crizotinib product Xalkori in form of oral pellet. Xalkori was previously authorized as an oral capsule.
Crizotinib Market Report Insights :
| Report Attributes | Report Details |
| Study Timeline | 2017-2031 |
| Market Size in 2031 | USD 1,505.14 Million |
| CAGR (2023-2031) | 5.6% |
| By Capsule | 200mg capsule and 250mg capsule |
| By Application | ALK-positive NSCLC and ROS1-positive NSCLC |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Players | Pfizer, Bulat Pharmaceutical, Beacon Pharmaceuticals PLC, Selleck Chemicals, Incepta Pharmaceuticals Ltd, Shanghai Hope-Chem Co.,Ltd ,WUHAN HANWAYS PHARMCHEM CO., LTD., DEAFARMA, Apothecon Pharmaceuticals Pvt Ltd., LGM Pharma, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd, MANUS AKTTEVA BIOPHARMA LLP, Vea Impex (I) Pvt. Ltd |
Key Questions Answered in the Report
How big is the Crizotinib market? +
The Crizotinib market is estimated to reach over USD 1,495.21 Million by 2032 from a value of USD 998.59 Million in 2024 and is projected to grow by USD 1,032.90 Million in 2025, growing at a CAGR of 5.6% from 2025 to 2032.
What specific segmentation details are covered in the Crizotinib report? +
The Crizotinib report includes specific segmentation details for capsule, application, and regions.
Which is the fastest segment anticipated to impact the market growth? +
In the Crizotinib market, 250 mg capsule is the fastest-growing segment during the forecast period.
Who are the major players in the Crizotinib market? +
The key participants in the Crizotinib market are Pfizer (US), Bulat Pharmaceutical (India), Beacon Pharmaceuticals PLC (Bangladesh), LGM Pharma (US), Hefei Home Sunshine Pharmaceutical Technology Co., Ltd (China), Selleck Chemicals (US), Shanghai Hope-Chem Co., Ltd (China), DEAFARMA (Italy), Incepta Pharmaceuticals Ltd (Bangladesh), WUHAN HANWAYS PHARMCHEM CO., LTD. (China) and others.
What are the key trends in the Crizotinib market? +
The Crizotinib market is shaped by several key trends including increasing awareness, technological advancement, and advancements in targeted therapy.